Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners

BACKGROUND: Levodopa‐carbidopa intestinal gel (LCIG, designated in the United States as carbidopa‐levodopa enteral suspension, CLES) was approved in the United States in 2015 for the treatment of refractory motor fluctuations in individuals with Parkinson disease (PD). Many neurologists in the Unite...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mov Disord Clin Pract
Autores principales: Burack, Michelle, Aldred, Jason, Zadikoff, Cindy, Vanagunas, Arvydas, Klos, Kevin, Bilir, Bahri, Fernandez, Hubert H., Standaert, David G.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2018
Materias:
Reviews
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6174493/
https://ncbi.nlm.nih.gov/pubmed/30363427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12630
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares